ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2307건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2258 | Recruiting | A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19 | COVID-19 | Drug: QLS1128 Drug: QLS1128 Drug: Placebo |
Phase 2 | Qilu Pharmaceutical Co., Ltd. | INDUSTRY | 360 | All | 18 Years ~ 80 Years | Qilu Pharmaceutical Co., Ltd., Jinan, Shandong, China |
| 2257 | Completed | A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19). | COVID-19 | Drug: Infliximab | Phase 2 | Tufts Medical Center, National Institutes of Health (NIH) | OTHER | 17 | All | 18 Years | Tufts Medical Center, Boston, Massachusetts, United States |
| 2256 | Terminated | A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19 | Severe to Critical COVID 19 With Associated ARDS | Drug: FP-025 100 mg Drug: FP-025 300 mg Drug: Placebo |
Phase 3 | Foresee Pharmaceuticals Co., Ltd. | INDUSTRY | 90 | All | 18 Years | Velocity Chula Vista, Chula Vista, California, United States Velocity San Diego, La Mesa, California, United States Shady Grove Medical Center, Rockville, Maryland, United States University of Nevada, Las Vegas (UNLV) School of Medicine, Las Vegas, Nevada, United States Trinity Health Center, Minto, North Dakota, United States Legacy Health, Portland, Oregon, United States Houston Methodist, Houston, Texas, United States United Medical Memorial Hospital, Houston, Texas, United States |
| 2255 | Terminated | A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) | Covid19 | Drug: ALLOCETRA-OTS Other: Placebo |
Phase 2 | Enlivex Therapeutics Ltd. | INDUSTRY | 12 | All | 18 Years ~ 85 Years | Hadassah Ein Kerem Medical Center, Jerusalem, Israel |
| 2254 | Completed | A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells) | COVID-19 | Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen Biological: Low-dose placebo (18-59 years) & Two dose regimen Biological: Low-dose placebo (18-59 years) & Three dose regimen Biological: High-dose placebo (18-59 years) & Two dose regimen Biological: High-dose placebo (18-59 years) & Three dose regimen Biological: Low-dose placebo (60-85 years) & Two dose regimen Biological: Low-dose placebo (60-85 years) & Three dose regimen Biological: High-dose placebo (60-85 years) & Two dose regimen Biological: High-dose placebo (60-85 years) & Three dose regimen |
Phase 2 | Jiangsu Province Centers for Disease Control and Prevention, West China Hospital | NETWORK | 960 | All | 18 Years ~ 85 Years | Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China |
| 2253 | Recruiting | A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) | COVID-19 | Biological: Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) Biological: Recombinant COVID-19 Variant Vaccine (Sf9 Cell) Biological: Placebo |
Phase 3 | WestVac Biopharma Co., Ltd., WestVac Biopharma (Guangzhou) Co., Ltd. | INDUSTRY | 4800 | All | 18 Years | Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China |
| 2252 | Unknown status | A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 | SARS-CoV-2 | Biological: Biological: oral polio vaccine Biological: Comparable Placebo Drug: NA-831 Drug: Comparable Placebo of drug Combination Product: Combination of oral polio vaccine and NA-831 Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug |
Phase 3 | NeuroActiva, Inc., Biomed Industries, Inc. | INDUSTRY | 3600 | All | 18 Years | Coronavirus Research Institute- Testing Site, Los Angeles, California, United States Coronavirus Research Institute, Orange, California, United States Coronavirus Research Institute-Testing Site, Palo Alto, California, United States Coronavirus Research Testing Site, San Francisco, California, United States Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States Coronavirus Research Institute, Sunnyvale, California, United States Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States Coronavirus Research Institute-Testing Site-, Bronx, New York, United States NeuroActiva-Clinical Research Unit, Auckland, New Zealand NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd, Auckland, New Zealand |
